{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:12:14Z","timestamp":1774055534522,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: This study aimed to evaluate the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy (wTP) in patients with ovarian cancer who developed carboplatin hypersensitivity reaction (HSR). Methods: We retrospectively investigated 86 patients with ovarian, fallopian tube, and peritoneal carcinoma who developed carboplatin HSR during previous chemotherapy (carboplatin and paclitaxel) at our institution between 2011 and 2019. After premedication was administered, paclitaxel was administered over 1 h, followed by cisplatin over 1 h (paclitaxel 80 mg\/m2; cisplatin 25 mg\/m2; 1, 8, 15 day\/4 weeks). We investigated the incidence of patients who successfully received wTP for at least one cycle, treatments compliance, progression-free survival (PFS), and overall survival (OS). Results: The median number of wTP administration cycles was 4 (Interquartile Range IQR, 3\u20137), 71 patients (83%) successfully received wTP, and 15 patients (17%) developed cisplatin HSR. The efficacy of treatment was as follows: 55 (64%) patients completed the scheduled wTP, 9 (10%) patients discontinued due to HSR to cisplatin within 6 cycles, 1 (1%) patient discontinued due to renal toxicity (grade 2) at the 6th cycle, and 21 (24%) patients discontinued due to progressive disease within 6 cycles. The median PFS and OS after administration of wTP were 10.9 months (95% CI: 7.7\u201317.7) and 25.9 months (95% CI: 19.0\u201350.2), respectively. Conclusions: wTP was safe and well-tolerated in patients who developed carboplatin HSR.<\/jats:p>","DOI":"10.3390\/cancers13040640","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T08:33:48Z","timestamp":1612514028000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5674","authenticated-orcid":false,"given":"Shinichi","family":"Tate","sequence":"first","affiliation":[{"name":"Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Nishikimi","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoyo","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-2205","authenticated-orcid":false,"given":"Makio","family":"Shozu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bartoletti, M., Pelizzari, G., Gerratana, L., Bortot, L., Lombardi, D., Nicoloso, M.S., Scalone, S., Giorda, G., Baldassarre, G., and Sorio, R. (2020). Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113805"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_5","unstructured":"(2020, May 29). Meeting Library|Randomized Phase III Study to Evaluate the Impact of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: Final Analysis of AGO DESKTOP III\/ENGOT-ov20. Available online: https:\/\/meetinglibrary.asco.org\/record\/185438\/abstract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical Features of Hypersensitivity Reactions to Carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1447-0756.2012.01893.x","article-title":"Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies","volume":"39","author":"Michikami","year":"2012","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ygyno.2018.10.037","article-title":"Outpatient de-sensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions","volume":"152","author":"Vetter","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/gyno.2001.6513","article-title":"Hypersensitivity Reactions to Carboplatin","volume":"84","author":"Markman","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1447-0756.2012.01917.x","article-title":"Re-treatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reac-tion to carboplatin","volume":"39","author":"Arimoto","year":"2013","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of cisplatin without desensitization after car-boplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2016.10.023","article-title":"Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin","volume":"144","author":"Bergamini","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Huang, C.-Y., Cheng, M., Lee, N.-R., Huang, H.-Y., Lee, W.-L., Chang, W.-H., and Wang, P.-H. (2020). Comparing Paclitaxel\u2013Carboplatin with Paclitaxel\u2013Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC serous-Type Tubo-Ovarian Cancer. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17072213"},{"key":"ref_17","first-page":"1846","article-title":"Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer","volume":"55","author":"Nagata","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00280-013-2130-0","article-title":"Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer","volume":"71","author":"Tsuburaya","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/IGC.0000000000000307","article-title":"Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin","volume":"25","author":"Kolomeyevskaya","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/gyno.1994.1098","article-title":"Death from Anaphylaxis to Cisplatin: A Case Report","volume":"53","author":"Zweizig","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2019.01.057","article-title":"Low Cross-Reactivity Between Cisplatin and Other Platinum Salts","volume":"7","author":"Pasteur","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00520-011-1123-y","article-title":"Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma","volume":"20","author":"Genc","year":"2011","journal-title":"Support. Care Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.23249","article-title":"Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: A Canadian Pediatric Brain Tumor Consortium experience","volume":"112","author":"Sung","year":"2008","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): Primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Luck","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:20:08Z","timestamp":1760160008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13040640"],"URL":"https:\/\/doi.org\/10.3390\/cancers13040640","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]}}}